Adaptin Bio APTN
OTC APTN
$6.27 +0.00 (+0.00%)
At close: Aug 19, 2026 · 4:00 PM EDT

Adaptin Bio (APTN) Long-Term Deferred Tax (2022 - 2023)

Adaptin Bio's (APTN) quarterly Long-Term Deferred Tax came in at $81335.0 in Q4 2023, up 192.53% year-over-year from $27804.0 in Q4 2022, and up 192.53% quarter-over-quarter from $27804.0 in Q4 2022.

Analysis

Adaptin Bio (APTN) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends

Adaptin Bio has disclosed Long-Term Deferred Tax across 2 years of filings, most recently posting $81335.0 for Q4 2023.

  • In Q4 2023, Long-Term Deferred Tax rose 192.53% year-over-year to $81335.0; the TTM figure through Dec 2023 stood at $81335.0 (up 192.53% YoY), while the FY2023 annual figure was $81335.0, up 192.53% from the prior year.
  • Long-Term Deferred Tax came in at $81335.0 for Q4 2023 at Adaptin Bio, up from $27804.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $81335.0 in Q4 2023 to a low of $27804.0 in Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Krystal Biotech 10.27 Bn 9.43 Bn 112.79 Mn
2 CRISPR Therapeutics AG 5.17 Bn 5.17 Bn -
3 Iovance Biotherapeutics 3.79 Bn 3.49 Bn 55.72 Mn
4 Legend Biotech 3.68 Bn 2.71 Bn 251.50 Mn
5 uniQure 3.05 Bn 3.05 Bn 5.49 Mn
6 Beam Therapeutics 2.65 Bn 2.65 Bn -
7 Precigen 2.44 Bn 2.44 Bn 52.17 Mn
8 Sarepta Therapeutics 2.33 Bn 1.53 Bn 251.87 Mn
9 Vericel 1.99 Bn 1.83 Bn 56.40 Mn
10 Adaptin Bio 56.76 Mn 56.09 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 81,335.00
Dec 31, 2022 27,804.00